Statistics Review This study investigated the effect supplementation of 120 mg of Genistein for 12 months has on 24 prodromal Alzheimer's disease patients. The effect was measured through the amyloid-beta (AB) deposition in the global brain and analysed using 18F-flutemetamol uptake. 52 patients(aged 54 to 75) from neurology departments in two Spanish hospitals volunteered to participate, out of which 27 were recruited. Selection was based on whether the patients 'Mini-Mental State Examination (MMSE) score ? 24, and ApoE presence determination. A Positron Emission Tomography (PET) was also used to derive estimation of an amyloid-ß standardized uptake value ratio (SUVR). 14 patients were assigned Genistein (1 withdrew midway) and 13 patients were assigned a placebo (2 withdrew midway). Patients received 1 capsule of Genistein (60 mg) or an equally shaped and sized placebo capsule, administered orally twice per day, by a blind administrator. Analysis was conducted in R 3.6.1 version, along with other quantitative tests such as the Mann-Whitney test and the student t- test. The response variable is the AB plague deposition in the global brain, observed through 18F- flutemetamol uptake and measured in number of plagues. The response variable is quantitative. The null hypothesis (HO) is that taking Genistein supplements has no effect on the Aß plague deposition in the global brain. The P-value reported is p = 0.878. This P-value suggests that there is virtually no evidence that Aß plague deposition decreased because of Genistein supplements, indicating that there is inconclusive evidence to reject the null hypothesis.